GlobalData on MSN2d
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMDHigh-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...
Cumberland Pharmaceuticals saw its shares pop almost 34 percent on heavy volume Tuesday following positive results from a ...
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel ...
NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...
Shares of Cumberland Pharmaceuticals continued their eye-opening ascent Wednesday on heavy volume.
All Penny Stocks (English) on MSN2d
Pharma Stock Soars On Phase 2 AnnouncementReal-time index price for Nasdaq Composite (NASX), along with buy or sell indicators, analysis, charts, historical ...
The first successful phase II trial in Duchenne muscular dystrophy (DMD) heart disease rolled out from Cumberland Pharmaceuticals Inc., which said top-line findings from the experiment called Fight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback